MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Archives Of Orthopaedic And Trauma Surgery

  • August 29, 2026
Nighttime Intramedullary Nailing for Femoral Fractures Shows Comparable Outcomes: Analysis from a 13-Year Level I Trauma Center Study
  • Artsiom Abialevich
  • Vadim Benkovich
  • Vladislav Osinsky
  • Yosef Adiniaev
  • Ilan Tzaytlin
  • Yotam Heinemann
  • Asaf Acker
  • August 29, 2026
  1. The study analyzed 288 adult femoral fracture procedures treated with intramedullary fixation between January 2010 and January 2023.
  2. Nighttime procedures involved younger patients and higher rates of high-energy trauma compared to daytime procedures.
  3. Demographic factors such as BMI, diabetes, and prior medical history showed no significant differences between daytime and nighttime cohorts.
  4. The primary outcome measured was any postoperative complication, with secondary endpoints including radiographic abnormalities and specific complications.
  5. Statistical analyses included multivariable logistic regression to assess the relationship between nighttime surgery and postoperative complications.
...more

Jama Network Open

  • August 29, 2026
Mortality Risks Associated with Elective Atrial Fibrillation Ablation Procedures in Japan
  • Koichi Inoue
  • Koshiro Kanaoka
  • Yasunori Ueda
  • Haruhiko Abe
  • Kuniyasu Ikeoka
  • Tsuyoshi Mishima
  • Tatsuhisa Ozaki
  • Takuya Ohashi
  • Satoshi Osaki
  • Yoko Sumita
  • Yoshitaka Iwanaga
  • Yasushi Matsumura
  • Yasushi Sakata
  • August 29, 2026
  1. Elective atrial fibrillation ablation is a widely used procedure aimed at improving quality of life through symptom relief.
  2. Mortality estimates for AF ablation vary significantly, ranging from 0.05% in high-quality centers to 0.46% in broader administrative data.
  3. The Japanese Registry of All Cardiac and Vascular Disease provides a reliable dataset for assessing periprocedural mortality in AF ablation.
  4. The study focuses on elective AF ablation, excluding emergency cases to ensure accurate assessment of procedural safety.
  5. Outcomes measured include in-hospital mortality, 30-day readmission rates, and major complications related to the procedure.
...more

Drugs - Real World Outcomes

  • August 29, 2026
Efficacy and Safety of Reinitiating PD-1 Inhibitors Following Previous Immunotherapy in Older Adults (≥ 60 Years) with Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center
  • Xiao-Yue Jiang
  • Xin Li
  • Hui Huang
  • Min Pan
  • Qiu-Qiu Chen
  • Chun-Qiao Chen
  • August 29, 2026
  1. In older patients with advanced non-small-cell lung cancer, PD-1 inhibitor rechallenge yielded a 21.4% objective response rate.
  2. The median overall survival for older patients reinitiating PD-1 inhibitors was 11.3 months.
  3. Safety profiles in older patients aligned with known PD-1 inhibitor toxicities, necessitating close monitoring for pneumonitis and hepatic enzyme elevations.
  4. Exploratory analyses indicated improved overall survival associated with better ECOG performance status and reduced metastatic burden.
  5. Older adults with NSCLC often present unique clinical characteristics, highlighting the need for tailored treatment approaches.
...more

Obesity Surgery

  • August 29, 2026
Overcoming Administrative Hurdles: Exploring Challenges in the Evaluation Process for Metabolic and Bariatric Surgery in the U.S.
  • Rylee Barber
  • Stephen Moorhead
  • Kalina Siehl
  • Ronit Pathak
  • Mary K Bryant
  • August 29, 2026

Objective: To examine appointment accessibility and program requirements among patients pursuing metabolic and bariatric surgery (MBS) in North Carolina and Sou

...more

Acr Open Rheumatology

  • August 29, 2026
Decreased Levels of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Therapy Correlate with Responsiveness to Subsequent Biologic Treatments in Axial Spondyloarthritis Patients
  • Addison Pacheco
  • Patricia Remalante-Rayco
  • Nigil Haroon
  • Denis Poddubnyy
  • Robert D. Inman
  • August 29, 2026
  1. Approximately 40% of axial spondyloarthritis patients fail to respond to biologic treatments, including TNFis and IL17is.
  2. Increased type 1 interferon-regulated gene expression is observed in secukinumab nonresponders compared to responders.
  3. The study analyzed patients who did not respond to secukinumab after failing TNFi to assess subsequent biologic treatment outcomes.
  4. Peripheral blood mononuclear cells were isolated and analyzed to evaluate immunologic changes during biologic treatment.
  5. Most patients ultimately respond to a third biologic treatment, regardless of the class of the biologic.
...more

Journal Of Neuro-Oncology

  • August 29, 2026
Outcomes and hematologic side effects following whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation in patients with solid-tumor leptomeningeal disease: a systematic analysis
  • Mishaal Munir
  • Kavita Sehrawat
  • Hanan Hassan
  • Matthew Hall
  • Minesh P. Mehta
  • Jonathan. T. Yang
  • Rupesh Kotecha
  • August 29, 2026
  1. Leptomeningeal disease (LMD) is a complication of advanced solid tumors, notably breast cancer and non-small cell lung cancer.
  2. Management of LMD is complex and may involve systemic agents, intrathecal therapy, and various forms of radiotherapy.
  3. Proton craniospinal irradiation (CSI) may reduce radiation exposure to normal tissues compared to conventional photon CSI.
  4. Early studies suggest proton CSI may improve CNS progression-free survival and overall survival without increasing serious adverse events.
  5. A systematic review is needed to synthesize outcomes of different radiotherapy modalities for solid-tumor LMD due to existing evidence heterogeneity.
...more

Nature Medicine

  • August 29, 2026
Evaluating the Efficacy of Combined Antithrombotic Treatment with Strong Antiplatelet Agents in Patients with Atrial Fibrillation and Acute Coronary Syndrome: A Randomized Controlled Study
  • Konstantinos D. Rizas
  • Konstantinos Mourouzis
  • Dominik Rath
  • Christoph B. Olivier
  • Laura Elisa Villegas Sierra
  • Theofanis Korovesis
  • Amin Polzin
  • Amani Al Tawil
  • Reza Wakili
  • Lukas von Stuelpnagel
  • Katharina Mayer
  • Marion Janisch
  • Tanja Ulrich
  • Sarah Lang
  • Sebastian K. G. Maier
  • Florian Brattinger
  • Lorenz Bott-Flügel
  • Harilaos Bogossian
  • Konstantinos Iliodromitis
  • Luisa Freyer
  • Julius Steffen
  • Konstantin Stark
  • Elodie Eiffener
  • Lauren E. Sams
  • Tobias Petzold
  • Axel Linke
  • Felix M. Heidrich
  • Samuel Sossala
  • Saif Zako
  • Nikolaos Dagkonakis
  • Andreas Schäfer
  • Frank Edelmann
  • David M. Leistner
  • Mariya Maslarska
  • Fabian Knebel
  • Georg Nickenig
  • Blerim Luani
  • Tienush Rassaf
  • Hüseyin Ince
  • Ibrahim Akin
  • Micha T. Maeder
  • Meinrad Gawaz
  • Hans-Josef Feistritzer
  • Norbert Frey
  • Stefan Kääb
  • Riza Sahin
  • Matthias Pauschinger
  • Thomas Stiermaier
  • Ingo Eitel
  • Marc Kollum
  • Jan Sebastian Wolter
  • Michael Schreinlechner
  • Axel Bauer
  • Christoph Stellbrink
  • Ulf Landmesser
  • Paulus Kirchhof
  • Dirk Sibbing
  • Holger Thiele
  • Adnan Kastrati
  • Ulrich Mansmann
  • Steffen Massberg
  • August 29, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Acr Open Rheumatology

  • August 29, 2026
The Role of Humanoid Assistants in Addressing the Rheumatology Workforce Shortage: A Look Ahead
  • Adam Kilian
  • Laura Upton
  • Joshua Samec
  • Shivang Chaudhary
  • Adam Friedman
  • Eva Waineo
  • Terry Moore
  • August 29, 2026
  1. The rheumatology workforce shortage is projected to exceed 100% by 2030, with significant implications for patient care access.
  2. Humanoid colleagues are defined as physically embodied robots capable of performing clinical tasks and engaging with patients.
  3. Humanoid systems could be trained through rheumatology fellowship programs, allowing for supervised clinical interactions.
  4. Accountability for AI interactions would remain with human clinicians, ensuring patient safety and educational oversight.
  5. Training humanoid trainees alongside fellows may enhance educational outcomes for both faculty and students.
...more

Dermatology And Therapy

  • August 29, 2026
Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma: Two-Year Findings from the AdjuMel Study
  • Stéphane Dalle
  • Philippe Saiag
  • Céleste Lebbé
  • Jean-Jacques Grob
  • Brigitte Dréno
  • Sophie Dalac
  • Bernard Asselain
  • François Skowron
  • Sophie Darras
  • Nicolas Jovenin
  • Gaëlle Quereux
  • Amir Khammari
  • Capucine Rieuf
  • Florence Brellier
  • Laurent Mortier
  • August 29, 2026
  1. Nivolumab is an approved adjuvant treatment for patients with completely resected stage III–IV melanoma, addressing rising mortality rates in Europe.
  2. The AdjuMel study evaluates real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected stage III–IV melanoma in France.
  3. At 2 years, relapse-free survival for patients in the study reached 52.8%, with lower recurrence rates in stage IIIA compared to IIIB–D.
  4. Tumor ulceration was linked to a higher risk of recurrence or death, while age also influenced outcomes, with younger patients faring better.
  5. The safety profile of adjuvant nivolumab remained consistent with previous reports, showing no adverse effects on health-related quality of life.
...more

Acta Neuropathologica

  • August 29, 2026
Elevated concentrations of cell-free hemoglobin and iron found in cerebral thrombi of stroke patients prior to the Omicron variant: new contributors to the prothrombotic effects of SARS-CoV-2
  • María Payá
  • Cristian Alcahut-Rodríguez
  • Rosa A. Barbella-Aponte
  • Francisco Hernández-Fernández
  • Juan D. Molina-Nuevo
  • Gemma Barroso-García
  • Beatriz Castro-Robles
  • Susana López-López
  • Lourdes Arias-Salazar
  • Óscar Ayo-Martín
  • Jorge García-García
  • Blanca Yélamos-Sanz
  • Natalia García-Flores
  • Alba G. Arandilla
  • Rafael Moreno-Luna
  • Alicia Aliena-Valero
  • Isabel Vielba-Gómez
  • José I. Tembl
  • Juan B. Salom
  • Gemma Serrano-Heras
  • Tomás Segura
  • August 29, 2026
  1. SARS-CoV-2 has led to over 777 million infections and 7 million deaths globally since its emergence in December 2019.
  2. COVID-19 increases the risk of cerebrovascular disease, with ischemic stroke occurring in approximately 1.5% of infected individuals pre-Omicron.
  3. COVID-19-related strokes are often cryptogenic, associated with poorer outcomes and higher NIHSS scores compared to non-COVID-19 strokes.
  4. The study investigates cerebral thrombi from COVID-19 patients to identify molecular drivers of the prothrombotic state linked to SARS-CoV-2.
  5. Elevated levels of cell-free hemoglobin and iron were found in cerebral thrombi, suggesting new contributors to the prothrombotic effects of SARS-CoV-2.
...more

Obesity Surgery

  • August 29, 2026
Initial Mental Health Conditions and Subsequent Psychiatric Results Following Metabolic-Bariatric Surgery: A Retrospective Cohort Analysis
  • Patricia M. Ortega
  • Luke Boyle
  • Dana Mahdi
  • Zahra Al-Essah
  • Ali Abdul Hussein
  • Mina Abdul Hussein
  • Aslesha Deshraju
  • Elena Brachimi
  • Prasidha Rai
  • Elsie Ampomah
  • Neha Hussain
  • Faizan Kiani
  • Mary Obigbesan
  • Lucy Tweedlie
  • Samantha Scholtz
  • Sanjay Purkayastha
  • Christos Tsironis
  • Sherif Hakky
  • Ravi Aggarwal
  • Ahmed R. Ahmed
  • Tricia Tan
  • Julia Kenkre
  • Kleopatra Alexiadou
  • Saira Hameed
  • Harvinder Chahal
  • Jonathan Cousins
  • Chioma Izzi-Engbeaya
  • August 29, 2026
  1. Metabolic-bariatric surgery (MBS) is the most effective treatment for severe obesity, leading to significant weight loss and reduced morbidity.
  2. Up to 50% of individuals seeking MBS have co-existing mental health conditions, which may impact postoperative recovery and quality of life.
  3. While depressive and anxiety symptoms often improve in the first year after MBS, long-term follow-up may reveal increased risks of self-harm and suicide.
  4. The study evaluated psychiatric and metabolic outcomes in adults undergoing MBS, focusing on the impact of pre-existing mental health conditions.
  5. Data were collected from a high-volume tertiary MBS unit, with a follow-up period of two years to assess outcomes related to mental health and weight loss.
...more

Journal Of Neuro-Oncology

  • August 29, 2026
Assessment of Radiological Changes in Primary Central Nervous System Lymphoma Following Corticosteroid Treatment and Its Prognostic Implications for Overall Survival: A Multicenter Analysis
  • Florian Scheichel
  • D. Pinggera
  • T. Rossmann
  • B. Popadic
  • S. Aspalter
  • V. Schön
  • A. Woehrer
  • M. M. Dorostkar
  • C. Dorfer
  • C. F. Freyschlag
  • F. Marhold
  • August 29, 2026
  1. Primary central nervous system lymphoma (PCNS-LBCL) accounts for approximately 3% of intracranial tumors.
  2. Corticosteroid therapy (CST) can lead to significant tumor regression in PCNS-LBCL, but responses vary widely among patients.
  3. The study involved a multicenter prospective analysis of patients scheduled for biopsy, with a focus on radiological changes post-CST.
  4. Eighteen patients were included in the prospective study after excluding those without a second MRI or with other diagnoses.
  5. Survival analysis aimed to determine if the radiological response to CST could predict overall survival in PCNS-LBCL patients.
...more

MDSpire News

  • August 28, 2026
FDA approves XFG-adapted COVID-19 vaccine
  • Kathryn Wighton
  • August 28, 2026
  • 2 min

Objective: To inform about the FDA approval of the XFG-adapted COVID-19 vaccine for specific populations. Approach: Approval Details: The FDA approved Pfizer an

...more

MDSpire News

  • August 28, 2026
FDA approves bictegravir and lenacapavir for HIV
  • Kathryn Wighton
  • August 28, 2026
  • 2 min
  1. The FDA approved bictegravir and lenacapavir (Bixlenvo) for adults with HIV-1 who have RNA levels below 50 copies/mL.
  2. Bixlenvo combines bictegravir 75 mg and lenacapavir 50 mg in a once-daily tablet for HIV treatment.
  3. Approval was based on phase 3 ARTISTRY-1 and ARTISTRY-2 trials showing comparable virologic suppression.
  4. Participants switching to Bixlenvo reported improved fasting lipid measures and treatment satisfaction.
  5. Common adverse reactions included headache, nausea, and diarrhea, with no new safety concerns identified.
...more

MDSpire News

  • August 28, 2026
FDA expands tirzepatide indication to cardiovascular risk reduction
  • Kathryn Wighton
  • August 28, 2026
  • 3 min
  1. The FDA approved tirzepatide to reduce major cardiovascular event risk in adults with type 2 diabetes at high risk.
  2. The approval includes reducing the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
  3. The indication was based on the SURPASS-CVOT trial, which involved 13,299 participants with type 2 diabetes.
  4. Tirzepatide was found noninferior to dulaglutide for major adverse cardiovascular events over a median follow-up of 4 years.
  5. Common adverse events with tirzepatide included gastrointestinal issues, generally mild to moderate in severity.
...more

MDSpire News

  • August 28, 2026
FDA approves oral dermatomyositis therapy
  • Kathryn Wighton
  • August 28, 2026
  • 2 min

Objective: To announce the FDA approval of brepocitinib as the first oral treatment for dermatomyositis. Approach: Study Design: A phase 3 randomized, double-bl

...more

MDSpire News

  • August 28, 2026
AI may ease patient decision-making in rhinology
  • Andrea Surnit
  • August 28, 2026
  • 4 min
  1. Patients with chronic rhinosinusitis or nasal obstruction experienced reduced decisional conflict using ChatGPT or Google.
  2. The study involved 57 English-speaking adults randomized to use ChatGPT or Google after counseling with a rhinologist.
  3. Mean Decisional Conflict Scale scores decreased significantly in both groups, but no statistical difference was found between them.
  4. Neither intervention improved treatment preferences or knowledge, and usability scores were similar for both platforms.
  5. The study's limitations included a small sample size and the single-center design, affecting generalizability of the findings.
...more

MDSpire News

  • August 28, 2026
Newborn variants may flag childhood cancer predisposition
  • Andrea Surnit
  • August 28, 2026
  • 4 min

Objective: To identify pathogenic or likely pathogenic cancer-predisposition variants in newborns and estimate their association with early-onset cancers. Appro

...more
2 min